Table 1.
Characteristics of patients with RA and ADL/physical mobility status.
| N = 59 | |
|---|---|
| Age (y) | 67.1 ± 12.0 |
| Male–female ratio (n) | 0:59 |
| Disease duration (y) | 21.3 ± 13.1 |
| Weight (kg) | 49.2 ± 8.5 |
| BMI (kg/m2) | 21.5 ± 3.44 |
| Steinbrocker stage (I, II, III, IV) (n) | 0, 7, 12, 40 |
| Steinbrocker class (I, II, III, IV) (n) | 0, 36, 23, 0 |
| DAS28-CRP score | 2.77 ± 0.85 |
| Prednisolone usage (%) | 50.8 |
| Prednisolone dosage (mg/day) | 1.9 ± 2.4 (0–10) |
| Methotrexate usage (%) | 67.8 |
| Biologics usage (%) | 23.7 |
| Biologics used (n) | TCZ: 5, IFX: 3, ETN: 3, ABT: 3 |
| SAFE-Q (Physical functioning/Social functioning) |
62.55 ± 19.11/63.95 ± 25.40 |
| mHAQ score (points) | 0.71 ± 0.7 |
| TUG average time (seconds) | 14.9 ± 12.1 |
Data are presented as means ± SD unless otherwise noted. BMI: body mass index, SAFE-Q: Self-Administered Foot Evaluation Questionnaire, mHAQ: modified Health Assessment Questionnaire, TUG: timed-up-and-go test, TCZ: tocilizumab, IFX: infliximab, ETN: etanercept, ABT: abatacept.